MedTrace Logo

Microbiome in Atopic Dermatitis Under Systemic Therapy

NCT05099315 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-02-13

No results posted yet for this study

Summary

The skin microbiome plays a role in the pathogenesis of atopic dermatitis. However, it is unclear whether the range of microbiota on the skin is the cause or consequence of atopic skin inflammation.

The influence of new systemic therapies for the treatment of moderate to severe atopic dermatitis (such as biologics or Janus kinase inhibitors) on the skin microbiome is largely unknown.

The main aim of this scientific exploratory study is to investigate whether and how the skin microbiome changes in patients with moderate to severe atopic dermatitis during systemic therapy. This not only allows new hypotheses to be generated on the pathogenesis of atopic dermatitis, but also new objective scales for the severity of atopic dermatitis can be developed.

Conditions

Interventions

OTHER

not applicable, observational study

Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05099315 on ClinicalTrials.gov